Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Henlius Biotech, Inc.
  6. News
  7. Summary
    2696   CNE100003N76

SHANGHAI HENLIUS BIOTECH, INC.

(2696)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
16.92 HKD   +6.55%
05/19Henlius Biotech's Phase 3 Study of Cancer Therapy Meets Primary Endpoints
MT
05/19Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy
CI
05/18Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy for the Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma Met Primary Endpoints
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shanghai Henlius Biotech Rejigs Top-Level Management

12/01/2021 | 05:17am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
JIANGXI SPECIAL ELECTRIC MOTOR CO.,LTD 5.84% 22.1 End-of-day quote.6.45%
JIN TONG LING TECHNOLOGY GROUP CO., LTD. 0.00% 3.81 End-of-day quote.-39.62%
SHANGHAI HENLIUS BIOTECH, INC. 6.55% 16.92 Delayed Quote.-23.27%
SINOPHARM GROUP CO. LTD. 3.36% 19.08 Delayed Quote.12.50%
TIANMA MICROELECTRONICS CO., LTD. 0.98% 9.28 End-of-day quote.-28.73%
All news about SHANGHAI HENLIUS BIOTECH, INC.
05/19Henlius Biotech's Phase 3 Study of Cancer Therapy Meets Primary Endpoints
MT
05/19Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an Internation..
CI
05/18Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of Hansizhuang (Serplul..
CI
05/18Henlius Biotech Wins Nod to Ramp Up Production of Cancer Drug at Upgraded Chinese Plant
MT
05/13Henlius And Eurofarma Entered Into A License Agreement For Henlius' 3 Products In Latin..
AQ
05/12Henlius Biotech Grants Brazil's Eurofarma Rights to Develop, Sell Cancer Drugs in Latin..
MT
05/11Shanghai Henlius Biotech, Inc. Enters into License Agreement with Eurofarma Laboratorio..
CI
04/28SHANGHAI HENLIUS BIOTECH : Voluntary announcement - first patient has been dosed in a phas..
PU
04/28Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX26 (A Rec..
CI
04/28Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in Phase 3 Clinic..
CI
More news
Financials
Sales 2022 2 869 M 429 M 429 M
Net income 2022 -403 M -60,2 M -60,2 M
Net cash 2022 2 522 M 377 M 377 M
P/E ratio 2022 -20,2x
Yield 2022 -
Capitalization 7 842 M 1 172 M 1 172 M
EV / Sales 2022 1,85x
EV / Sales 2023 2,86x
Nbr of Employees 2 234
Free-Float 21,6%
Chart SHANGHAI HENLIUS BIOTECH, INC.
Duration : Period :
Shanghai Henlius Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI HENLIUS BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 14,43 CNY
Average target price 22,70 CNY
Spread / Average Target 57,3%
EPS Revisions
Managers and Directors
Wen Jie Zhang Chairman & Chief Executive Officer
Jun Zhu President
Gino Li Chief Financial Officer & Vice President
Rong Li Feng Chairman-Supervisory Board
Wei Dong Jiang Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
SHANGHAI HENLIUS BIOTECH, INC.-23.27%1 172
CSL LIMITED-5.75%93 148
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
WUXI BIOLOGICS (CAYMAN) INC.-43.60%30 261
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130